McKesson Corporation (MCK)

US — Healthcare Sector
Peers: COR  VRTX  CVS  MDT  HCA  GSK  BMY  CAH  SNY  SYK 

Automate Your Wheel Strategy on MCK

With Tiblio's Option Bot, you can configure your own wheel strategy including MCK - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol MCK
  • Rev/Share 3023.1785
  • Book/Share -6.9095
  • PB -52.0018
  • Debt/Equity -5.0498
  • CurrentRatio 0.8829
  • ROIC 0.1716

 

  • MktCap 102369370905.0
  • FreeCF/Share 45.9888
  • PFCF 17.822
  • PE 32.3285
  • Debt/Assets 0.1222
  • DivYield 0.0037
  • ROE -1.2479

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 2
  • DCF Score 5
  • P/B Score 1
  • D/E Score 1

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation MCK Barclays -- Overweight -- $960 Dec. 9, 2025
Resumed MCK Mizuho -- Neutral -- $630 Dec. 4, 2024
Downgrade MCK Robert W. Baird Outperform Neutral $603 $531 Sept. 24, 2024
Reiterated MCK Leerink Partners -- Outperform $670 $665 Sept. 5, 2024

News

McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
MCK
Published: March 04, 2025 by: Seeking Alpha
Sentiment: Neutral

McKesson Corporation (NYSE:MCK ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Britt Vitalone – Executive Vice President and Chief Financial Officer Conference Call Participants Unidentified Analyst Good morning. Thanks for joining us for the next session here at the TD Cowen Healthcare Conference and very pleased to have with us McKesson.

Read More
image for news McKesson Corporation (MCK) TD Cowen 45th Annual Healthcare Conference Transcript
Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?
MCK
Published: February 11, 2025 by: Zacks Investment Research
Sentiment: Positive

McKesson MCK delivered an 18% increase in revenues ($95.3 billion) and a 16% rise in adjusted operating profit during the third quarter of fiscal 2025 despite ongoing macroeconomic challenges. The company also raised its full-year guidance.

Read More
image for news Should You Buy, Hold or Sell MCK Stock Following Robust Q3 Earnings?

About McKesson Corporation (MCK)

  • IPO Date 1994-11-10
  • Website https://www.mckesson.com
  • Industry Medical - Distribution
  • CEO Brian S. Tyler
  • Employees 44000
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.